ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

American VC firm Arch launches $3bn biomedical fund with eye on Japan

Fund looks to help develop startups short on capital, co-founder says

Japan has promising biotech startups that often lack the support needed to bring their technology to market. (Photo courtesy of Chordia Therapeutics)

TOKYO -- U.S.-based Arch Venture Partners has launched a $3 billion venture capital fund specializing in medical technologies, one of the world's largest of its kind, with Japanese startups among its potential targets.

The new fund will add about 40 companies to its portfolio over three to four years, Arch co-founder Keith Crandell told Nikkei. It will invest capital from universities and institutional investors in emerging enterprises, with a focus on cutting-edge technology in such fields as drug development, genome editing and cell therapy.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more